Kailera Therapeutics completes enrollment in global Phase 3 ribupatide program
KLRA•Kailera Therapeutics said enrollment is complete in its Kainetic global Phase 3 program for ribupatide injection. Topline trial data are expected in mid-2028.
1. Enrollment completed
Kailera Therapeutics announced completion of enrollment in its Kainetic global Phase 3 clinical program of ribupatide injection, a GLP-1/GIP receptor dual agonist. The company expects topline data from the Phase 3 trials in mid-2028.
